Research
Hormonal
Lowering LDL cholesterol levels directly reduces the incidence of cardiovascular disease events, establishing a causal dose-response relationship where lower levels yield greater benefit.
If you have diabetes, heart disease, or high cardiovascular risk, keeping your LDL cholesterol as low as possible is the most effective way to prevent heart attacks and strokes. Focus on treatments that lower LDL, such as statins and lifestyle changes, as this directly reduces your risk.
StrongSupportsVERY_HIGH confidence
The totality of evidence overwhelmingly supports the centrality of elevated plasma cholesterol levels as a predictor of the development of atherosclerosis... Experimental studies directly support the central role of LDL in atherogenesis... Animal and human trials of dietary and pharmacological interventions that reduce LDL cholesterol are associated with stabilization and regression of atherosclerosis in proportion to the cholesterol lowering achieved, supporting the validity of 'the lower the cholesterol the better' notion
Why this rating
Based on extensive animal models, human genetic data (LDL receptor mutations), and multiple randomized controlled trials cited.
Source
Lipoprotein Management in Patients With Cardiometabolic Risk
John D. Brunzell et al. · Diabetes Care · 2008
DOI 10.2337/dc08-9018
clinical_guidelineCited 708×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
- In patients with high triglycerides or metabolic syndrome, non-HDL cholesterol is a superior predictor of cardiovascular risk and a valid secondary treatment target compared to LDL cholesterol alone.Good
- ApoB and LDL particle number (measured by NMR) are superior predictors of cardiovascular risk and residual risk on therapy compared to LDL cholesterol or non-HDL cholesterol in patients with cardiometabolic risk.Good
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →